Share
830 Posts.
lightbulb Created with Sketch. 1125
clock Created with Sketch. 09/06/21
10:18
Share
Originally posted by Silverchair:
↑
Clinuvel is making a LOT of money right now from one single rare indication (EPP) and that is with US sales only just beginning. This "golden goose" you describe is not going to face competition from generics this decade imo. If you understood the company you would realise this "golden goose" is actually just the proof-of-concept disease that shows the amazing safety of the clinuvel drug and at the same time gathers data and gives authorities confidence in the company and what other diseases they can potentially treat. This is where you are going to see the real BIG FARM OF GOLDEN GEESE when Clinuvel get approval for their existing drug to treat Vitiligo, XP, VP, OTRs (organ transplant recipients), skin cancer sufferers, Stroke victims (85% of 15 Million currently untreated) and with their OTC products for people who want solar protection and DNA repair - so pretty much everyone! This mostly will come not from new drugs but from an existing FDA, EMA, TGA and Israel approved drug that is very safe and is now seeking new and currently untreated indications. This is a much simpler process than getting a new drug approved because safety is already proven - and if CUV gets approval for just one of the other indications it will make this a $100+ stock overnight.
Expand
Algos working hard this morning to depress the price of CUV (as usual). However, it doesn't change the fundamentals of anything to do with this company. Record revenues and profits are only weeks away now, a trial into one of the blockbuster indications in Stroke has commenced and Wolgen mentioned in the chat with Dr David Stanton of Jefferies that over 40 US treatment centres are accredited so growth in the worlds biggest EPP markets is going gangbusters.
(20min delay)